Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease. The Company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its programs in atopic dermatitis and targeted orphan indications.
Azitra is a clinical-stage medical dermatology company that leverages its extensive knowledge of proteomics, genetic engineering, and the skin microbiome to create and develop novel products for the treatment of skin conditions and diseases. The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory, is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis. Direct application of these commensal bacteria alone improves skin appearance, hydration, and healing.
Total Funding: $37.8 M
Funding Stage: Series B
Business Stage: Scaling Up
Market: B2C
Company Size: 1 to 25
Founded: 2014
Research Associate - Analytical Chemistry and Bioanalysis
Montreal, Quebec
Research Technician - Bioanalysis
Montreal, Quebec
Research Scientist – Molecular Microbiologist
Branford, Connecticut
